

Bispecific Antibodies: A Review for Non-Oncology Clinicians

Michelle L. Wehbe, Steven R. Schuster, MD

University of Colorado – Anschutz School of Medicine at Colorado State University, UC Health Cancer Care and Hematology

Abstract

Bispecific antibodies (BsAbs) are engineered immunotherapies that contain two distinct antigen-binding sites, enabling simultaneous engagement of tumor and immune effector cells and driving targeted cytotoxicity. This review provides a practical overview of BsAbs for non-oncology clinicians, emphasizing core pharmacologic principles, approved indications, and recognition of treatment related toxicities. We first outline BsAb structure and mechanisms of action and summarize the rapid expansion of FDA approved agents across indications. We then review key adverse effects, highlighting consensus grading systems and frontline management strategies relevant to primary care, emergency, and inpatient settings. Finally, we propose an approach for non-oncology clinicians evaluating patients receiving BsAbs, focusing on early recognition of symptoms, appropriate initial workup and supportive care, and timely consultation with specialists. This framework aims to equip non-oncology clinicians to safely participate in the care of a growing population of patients treated with BsAbs across diverse care environments.